U.S. patent 8,372,816, titled “Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA” was issued to Dicerna. This issuance continues the expansion of Dicerna’s patent portfolio around RNAi-related technology.
Domain Associates and Elite Consulting Collaborate to Create and Invest in Life Science Companies in ChinaMarch 13, 2013
The partnership called Domain Elite will establish new companies and JVs in China that will provide Western companies the financing, regulatory, medical, and marketing support and infrastructure needed to bring their breakthrough products to China.
Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal FatMarch 12, 2013
The first patient has been treated with LIPO-202 in Lithera’s 500-patient Phase 2b “RESET” trial. LIPO-202, Lithera’s lead product candidate, is a novel injectable pharmaceutical product designed to produce localized reduction of subcutaneous fat.